GLP-1 drugs are quickly becoming some of the most ubiquitous in the U.S., and they have drawn interest for their potential ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently a pressing public health issue associated with ...

New findings presented at ASH indicated that GLP-1 agonists led to a significant reduction in the risk for dangerous blood ...

The term "nonalcoholic fatty liver disease" (NAFLD) has long been used to describe liver steatosis not related to excessive alcohol consumption ...

A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...

Scientists uncover how TRH neurons suppress hunger by inhibiting AgRP neurons, advancing our understanding of GLP-1-based ...

By Vijay Kumar Malesu With evidence from 85,373 participants across 11 trials, GLP-1 receptor agonists significantly reduced ...